Research brief · Metabolic health
Eloralintide.
The amylin approach.
Often called Elora, eloralintide is an experimental peptide being studied for weight management. Here is what the human evidence says, and what remains unanswered.
A different fullness signal
Eloralintide is a long-acting analogue of amylin, a hormone released alongside insulin. It targets amylin receptors involved in fullness and food intake. Cell studies show a preference for the AMY1 receptor over the calcitonin receptor. It is not a GLP-1 receptor agonist. [1]
Receptor selectivity helps explain why researchers are studying the molecule. It does not, by itself, prove better tolerability or muscle preservation in people. Findings from rodents and early laboratory experiments need human confirmation. [1]
What the published trial found
263 adults · 48 weeks
Without type 2 diabetes
Peer-reviewed · The Lancet, 2025
A randomized phase 2 trial enrolled adults with obesity, or overweight plus a related condition. The highest mean weight reduction was 20.1%, versus 0.4% with placebo, under the efficacy analysis. [2]
That analysis estimates the effect assuming participants remained on treatment. The treatment-regimen analysis, which addresses discontinuation, estimated 17.5% versus 2.3% for the same comparison. Nausea and fatigue were common, with tolerability varying by dose and escalation schedule. [2]
This Lilly-funded study supports further research. It does not establish long-term safety, cardiovascular benefit, or superiority to another medicine tested in a different trial.
EloraTZP is a combination
367 adults · 48 weeks
With type 2 diabetes
Sponsor / conference report · Phase 2b
On September 30, Lilly reported results for eloralintide plus tirzepatide in adults with obesity or overweight and type 2 diabetes. The highest combination arm had mean weight reduction of 23.3% versus 14.8% with tirzepatide alone, using the efficacy estimand. The primary comparison was against placebo; the tirzepatide comparison was secondary. [3]
Tolerability matters: gastrointestinal events were more frequent with the combination. Adverse events led to discontinuation in 10.8–27.0% across combination arms versus 2.9% with tirzepatide. [3]
These are preliminary combination findings, not eloralintide-alone results. The efficacy analysis assumes continued treatment. Lilly plans phase 3 trials of a co-formulation in late 2026; the phase 2b study used separate injections. This is not a self-combination protocol. [3]
What comes next
Eloralintide remains investigational as of October 1, 2026. A research-vendor listing or an FDA substance identifier does not constitute drug approval. Trial findings apply to the studied pharmaceutical product and population, not to unidentified products sold online. [3] [6]
- ENLIGHTEN-1 studies eloralintide in adults with obesity or overweight without type 2 diabetes.
- ENLIGHTEN-2 studies adults with obesity or overweight and type 2 diabetes.
- ENLIGHTEN-6 studies eloralintide added to ongoing incretin treatment.
These phase 3 registry records listed recruitment at review. Enrollment and completion dates can change; check the linked records for current status. [4]
Questions the evidence still needs to answer
How durable are the results? How do benefits and harms compare over longer follow-up? Who can tolerate treatment? Do body-composition and clinical outcomes improve? Weight change alone cannot answer all of these questions.
For personal weight-management decisions, discuss approved options and clinical-trial eligibility with a licensed clinician.
Primary sources
Publication, registry and sponsor evidence are labeled separately.
- Eloralintide discovery and translational research. Peer-reviewed mechanism and preclinical/early human work. Also known in development as AMY1176.
- Billings and colleagues: eloralintide phase 2 randomized trial. The Lancet (2025), DOI 10.1016/S0140-6736(25)02155-5. Trial: NCT06230523. Efficacy and treatment-regimen estimates should be distinguished.
- Lilly: EloraTZP phase 2b results, September 30, 2026. Sponsor announcement of EASD conference findings. A full peer-reviewed report was not located in our October 1 review. Trial: NCT06603571.
- ClinicalTrials.gov phase 3 records: ENLIGHTEN-1, ENLIGHTEN-2, ENLIGHTEN-6. Registry updates dated September 22, 2026; checked October 1.
- Full-text translational study. Animal findings and small early human studies have different evidentiary limits from later randomized trials.
- FDA substance identity record for eloralintide. The FDA explicitly distinguishes a UNII identifier from regulatory approval.